title: Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release.
abstract: In previous studies, we showed that blood monocyte elaboration of interleukin 1 (IL-1), a known stimulator of bone resorption, was higher in osteoporotic patients with rapid bone turnover than in those with slow turnover and in nonosteoporotic subjects. Since an acceleration of bone loss following menopause contributes to the risk of osteoporosis in women, we have studied the effects of menopause and ovarian steroid treatment on IL-1 release by monocytes obtained from nonosteoporotic and osteoporotic women. IL-1 activity in the monocyte culture medium derived from untreated postmenopausal women (nonosteoporotic and osteoporotic) was higher than in the medium derived from either untreated premenopausal or estrogen/progesterone-treated postmenopausal women. A significant negative correlation was found between IL-1 and years since menopause in both the healthy (r = -0.75; P less than 0.005) and the osteoporotic (r = -0.61; P less than 0.01) untreated postmenopausal women. The difference between the two slopes was significant at P less than 0.05. Premenopausal IL-1 levels were achieved within 8 years of menopause in the nonosteoporotic, but not in the osteoporotic, subjects in whom increases were evident as long as 15 years after menopause. IL-1 also correlated inversely with vertebral mineral density (r = -0.37; P less than 0.05), as measured by quantitative computed tomography. In prospective studies, treatment with estrogen/progesterone for 1 month caused a substantial highly significant decrease in IL-1 activity in each of three nonosteoporotic and five osteoporotic women, confirming the apparent effect of hormone therapy observed in the cross-sectional analysis. Although a cause-effect relationship has not been established, it is our hypothesis, based on these data, that alterations in IL-1 production may underlie the postmenopausal acceleration in bone loss and its inhibition by ovarian steroids. Persistent elevation of IL-1 secretion appears to be a feature of postmenopausal osteoporosis.
authors.affiliation: Division of Metabolism, Jewish Hospital of Saint Louis, MO 63110.
authors.forename: R
authors.initials: R
authors.lastname: Pacifici
authors.forename: L
authors.initials: L
authors.lastname: Rifas
authors.forename: R
authors.initials: R
authors.lastname: McCracken
authors.forename: I
authors.initials: I
authors.lastname: Vered
authors.forename: C
authors.initials: C
authors.lastname: McMurtry
authors.forename: L V
authors.initials: LV
authors.lastname: Avioli
authors.forename: W A
authors.initials: WA
authors.lastname: Peck
mesh_terms: D000328:Adult; D002478:Cells, Cultured; D003692:Delayed-Action Preparations; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000097:blood* / Q000378:metabolism; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008593:Menopause; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D010024:Osteoporosis / Q000097:blood* / Q000276:immunology; D012016:Reference Values; D012044:Regression Analysis
chemical_list: D003692:Delayed-Action Preparations; D004967:Estrogens; D007375:Interleukin-1; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone